Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prueba de la aplicación de la película Mepitel durante la radioterapia para reducir el enrojecimiento y la descamación relacionados con la radiación en pacientes con cáncer de mama después de una mastectomía

27 de agosto de 2026 actualizado por: Alliance for Clinical Trials in Oncology

Película de Mepitel para la reducción de la dermatitis por radiación en pacientes con cáncer de mama sometidas a radioterapia posmastectomía: ensayo clínico aleatorizado de fase III

This phase III trial studies how well Mepitel Film works in reducing radiation dermatitis (redness and peeling) in patients with breast cancer during radiation therapy after a mastectomy. Mepitel Film may reduce the severity of skin redness and peeling in the area of radiation.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

The primary and secondary objectives of the study:

PRIMARY OBJECTIVES:

I. To determine the ability of Mepitel Film to reduce the severity of radiation dermatitis in patients undergoing post-mastectomy radiotherapy for breast cancer when compared to the institutional standard of care.

KEY SECONDARY OBJECTIVES:

I. To determine the ability of Mepitel Film to prevent radiation-induced dermatitis based on a centralized, blinded provider assessment review of photographs.

II. To determine the ability of Mepitel Film to prevent radiation-induced dermatitis based on a non-blinded institutional provider assessment.

III. To determine the ability of Mepitel Film to prevent radiation-induced dermatitis based on a combined patient and non-blinded institutional provider assessment.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive standard of care skin management during radiation therapy for up to 6 weeks.

ARM II: Patients receive Mepitel Film applied to breast or chest wall as needed or once every 2 weeks before radiation therapy for up to 6 weeks.

After completion of study, patients are followed up at 7-14 days, 3 months, 6 months, 1 year, 2 years, then every 6 months up to 5 years.

Tipo de estudio

Intervencionista

Inscripción (Actual)

216

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Estados Unidos
    • California
      • Marysville, California, Estados Unidos, 95901
        • Fremont - Rideout Cancer Center
      • Truckee, California, Estados Unidos, 96161
        • Gene Upshaw Memorial Tahoe Forest Cancer Center
    • Delaware
      • Frankford, Delaware, Estados Unidos, 19945
        • Beebe South Coastal Health Campus
      • Newark, Delaware, Estados Unidos, 19713
        • Helen F Graham Cancer Center
      • Newark, Delaware, Estados Unidos, 19713
        • Medical Oncology Hematology Consultants PA
      • Rehoboth Beach, Delaware, Estados Unidos, 19971
        • Beebe Health Campus
    • Florida
      • Atlantis, Florida, Estados Unidos, 33462
        • John Fitzgerald Kennedy Medical Center
    • Iowa
      • Ames, Iowa, Estados Unidos, 50010
        • McFarland Clinic - Ames
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Mercy Hospital
      • Cedar Rapids, Iowa, Estados Unidos, 52403
        • Oncology Associates at Mercy Medical Center
      • Clive, Iowa, Estados Unidos, 50325
        • Mercy Cancer Center-West Lakes
      • Des Moines, Iowa, Estados Unidos, 50309
        • Iowa Methodist Medical Center
      • Des Moines, Iowa, Estados Unidos, 50314
        • Mercy Medical Center - Des Moines
      • Des Moines, Iowa, Estados Unidos, 50309
        • Medical Oncology and Hematology Associates-Des Moines
    • Maine
      • Bath, Maine, Estados Unidos, 04530
        • MaineHealth Coastal Cancer Treatment Center
      • Portland, Maine, Estados Unidos, 04102
        • Maine Medical Center-Bramhall Campus
      • Sanford, Maine, Estados Unidos, 04073
        • MaineHealth Cancer Care Center of York County
      • Scarborough, Maine, Estados Unidos, 04074
        • Maine Medical Center- Scarborough Campus
    • Maryland
      • Annapolis, Maryland, Estados Unidos, 21401
        • Anne Arundel Medical Center
      • Baltimore, Maryland, Estados Unidos, 21215
        • Sinai Hospital of Baltimore
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland/Greenebaum Cancer Center
      • Columbia, Maryland, Estados Unidos, 21044
        • Central Maryland Radiation Oncology in Howard County
      • Glen Burnie, Maryland, Estados Unidos, 21061
        • UM Baltimore Washington Medical Center/Tate Cancer Center
      • Towson, Maryland, Estados Unidos, 21204
        • UM Saint Joseph Medical Center
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48106
        • Saint Joseph Mercy Hospital
      • Brighton, Michigan, Estados Unidos, 48114
        • Saint Joseph Mercy Brighton
      • Livonia, Michigan, Estados Unidos, 48154
        • Trinity Health Saint Mary Mercy Livonia Hospital
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Mayo Clinic in Rochester
    • Missouri
      • Rolla, Missouri, Estados Unidos, 65401
        • Delbert Day Cancer Institute at PCRMC
      • Springfield, Missouri, Estados Unidos, 65804
        • Mercy Hospital Springfield
      • St Louis, Missouri, Estados Unidos, 63141
        • Mercy Hospital Saint Louis
    • Montana
      • Billings, Montana, Estados Unidos, 59101
        • Billings Clinic Cancer Center
    • New York
      • Glens Falls, New York, Estados Unidos, 12801
        • Glens Falls Hospital
      • White Plains, New York, Estados Unidos, 10601
        • Dickstein Cancer Treatment Center
    • North Dakota
      • Grand Forks, North Dakota, Estados Unidos, 58201
        • Altru Cancer Center
    • Pennsylvania
      • Meadowbrook, Pennsylvania, Estados Unidos, 19046
        • Holy Redeemer Hospital and Medical Center
    • South Carolina
      • Anderson, South Carolina, Estados Unidos, 29621
        • AnMed Health Cancer Center
      • Georgetown, South Carolina, Estados Unidos, 29440
        • Tidelands Georgetown Memorial Hospital
      • Greenville, South Carolina, Estados Unidos, 29607
        • Saint Francis Cancer Center
      • Greenville, South Carolina, Estados Unidos, 29601
        • Saint Francis Hospital
      • Greer, South Carolina, Estados Unidos, 29651
        • Gibbs Cancer Center-Pelham
      • Murrells Inlet, South Carolina, Estados Unidos, 29576
        • MUSC Health Tidelands Health Radiation Therapy Center
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Spartanburg Medical Center
    • Texas
      • Laredo, Texas, Estados Unidos, 78041
        • Doctor's Hospital of Laredo
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84112
        • Huntsman Cancer Institute/University of Utah
      • Salt Lake City, Utah, Estados Unidos, 84106
        • University of Utah Sugarhouse Health Center
    • Wisconsin
      • Appleton, Wisconsin, Estados Unidos, 54911
        • ThedaCare Regional Cancer Center
      • Wausau, Wisconsin, Estados Unidos, 54401
        • Aspirus Regional Cancer Center
      • Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
        • Aspirus Cancer Care - Wisconsin Rapids

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Histologic confirmation of breast malignancy with TNM staging.
  • Patients must have undergone a mastectomy with or without reconstruction within the past 120 days if not receiving adjuvant therapy, or within 60 days after completion of the last dose of chemotherapy.
  • No prior radiotherapy to any portion of the planned treatment site.
  • No documented history of adhesive or tape allergy.
  • Patients must be scheduled to receive conventionally fractionated photon-based radiation. Patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation or hypofractionated radiation are not eligible.
  • No active rash or pre-existing dermatitis within the treatment field.
  • No co-existing medical conditions resulting in life expectancy < 2 years.
  • No active collagen vascular diseases (i.e. lupus erythematosus, scleroderma, dermatomyositis).
  • No concomitant cytotoxic chemotherapy. Endocrine therapy and HER2 directed therapies are allowed.
  • No current inflammatory breast cancer, or gross dermal involvement at initiation of radiotherapy.
  • No previous history of organ or bone marrow transplant.
  • Age >= 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • In order to complete the mandatory patient-completed measures, participants must be able to speak and read English.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Prevención
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Arm I (standard of care)

Patients receive standard of care skin management during radiation therapy for up to 6 weeks.
Otro: Quality-of-Life Assessment

Ancillary studies

Otro: Questionnaire Administration

Ancillary studies

Otro: Best Practice

Receive standard of care

Otros nombres:
  • Estándar de cuidado
Experimental: Arm II (Mepitel Film)

Patients receive Mepitel Film applied to breast or chest wall every 2 weeks before radiation therapy for up to 6 weeks.
Otro: Quality-of-Life Assessment

Ancillary studies

Otro: Questionnaire Administration

Ancillary studies

Dispositivo: Wound Dressing Material

Apply Mepitel Film

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Serially Measured Patient-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores
Periodo de tiempo: Up to 5 months

Scores obtained at baseline (i.e. prior to the start of radiation), during weekly radiation therapy, at 10 (±4) days post-radiation therapy, and at 3-months post radiation therapy. At a given measurement time point, a patient-completed mRISRAS score ranges from 0 to 12, where higher scores correspond to increased radiation-induced skin reactions. The effect of the Mepitel Film in reducing the severity of radiation dermatitis will be defined as the between-arm difference in the summary statistic area under the curve obtained from a repeated-measures (means) mixed model.
Up to 5 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Centralized, Blinded Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores Obtained From a Blinded Grading of the Photographs Taken at the End of Radiation Therapy
Periodo de tiempo: Up to 2 months

At the completion of radiation therapy, photographs will be obtained one hour after the removal of the Mepitel Film or immediately following completion of radiation therapy for patients on the standard of care arm. A panel of radiation oncology providers will perform the blinded, central review to score the photographs. Each provider will independently assign a provider-completed mRISRAS score to each photograph, and the average score will be calculated for each patient. The provider-completed mRISRAS score ranges from 0 to 24, where higher scores correspond to increased radiation-induced skin reactions. The Wilcoxon rank-sum test will be used to test for an effect of the Mepitel Film.
Up to 2 months
Serially Measured Non-blinded Institutional Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores
Periodo de tiempo: Up to 5 months

Scores obtained at baseline (i.e. prior to the start of radiation), during weekly radiation therapy, at 10 (±4) days post-radiation therapy, and at 3-months post radiation therapy. At a given measurement time point, a provider-completed mRISRAS score ranges from 0 to 24, where higher scores correspond to increased radiation-induced skin reactions. The effect of the Mepitel Film in reducing the severity of radiation dermatitis will be defined as the between-arm difference in the summary statistic area under the curve obtained from a repeated-measures (means) mixed model.
Up to 5 months
Serially Measured Combined Patient- and Provider-completed Modified Radiation Induced Skin Reaction Assessment Scale (mRISRAS) Scores
Periodo de tiempo: Up to 5 months

Scores obtained at baseline (i.e. prior to the start of radiation), during weekly radiation therapy, at 10 (±4) days post-radiation therapy, and at 3-months post radiation therapy. At a given measurement time point, a provider-completed mRISRAS score ranges from 0 to 36, where higher scores correspond to increased radiation-induced skin reactions. The effect of the Mepitel Film in reducing the severity of radiation dermatitis will be defined as the between-arm difference in the summary statistic area under the curve obtained from a repeated-measures (means) mixed model.
Up to 5 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Alliance for Clinical Trials in Oncology

Colaboradores

National Cancer Institute (NCI)

Investigadores

  • Silla de estudio: Kimberly Corbin, MD, Mayo Clinic

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

26 de julio de 2022

Finalización primaria (Actual)

29 de mayo de 2024

Finalización del estudio (Estimado)

15 de febrero de 2029

Fechas de registro del estudio

Enviado por primera vez

26 de julio de 2021

Primero enviado que cumplió con los criterios de control de calidad

26 de julio de 2021

Publicado por primera vez (Actual)

4 de agosto de 2021

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • A221803
  • UG1CA189823 (Subvención/contrato del NIH de EE. UU.)
  • NCI-2019-04688 (Identificador de registro: NCI Clinical Trial Reporting Program)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir